| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NBT.1602 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nbt.1602 |
| P698 | PubMed publication ID | 20081866 |
| P5875 | ResearchGate publication ID | 41041519 |
| P50 | author | Pieter R. Cullis | Q88255217 |
| Barbara L. Mui | Q108795226 | ||
| P2093 | author name string | Kallanthottathil G Rajeev | |
| Martin A Maier | |||
| Muthiah Manoharan | |||
| Jianxin Chen | |||
| Muthusamy Jayaraman | |||
| Rene Alvarez | |||
| Akin Akinc | |||
| Kim F Wong | |||
| Qingmin Chen | |||
| Dinah W Y Sah | |||
| J Robert Dorkin | |||
| June Qin | |||
| Lubomir Nechev | |||
| Ying K Tam | |||
| Scott A Barros | |||
| Sean C Semple | |||
| Marco A Ciufolini | |||
| Masuna Srinivasulu | |||
| Michael J Hope | |||
| Mikameh Kazem | |||
| Mark A Tracy | |||
| Ed Yaworski | |||
| Ian MacLachlan | |||
| Kieu Lam | |||
| Lloyd B Jeffs | |||
| Thomas D Madden | |||
| Todd Borland | |||
| William L Cantley | |||
| Antonin de Fougerolles | |||
| Sandra K Klimuk | |||
| Ismail M Hafez | |||
| Soma De | |||
| Verbena Kosovrasti | |||
| Merete L Eisenhardt | |||
| Erin J Crosley | |||
| Ammen P Sandhu | |||
| Connie K Cho | |||
| Derrick Stebbing | |||
| Michael J Weinstein | |||
| P2860 | cites work | Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection | Q71099227 |
| Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo | Q73850372 | ||
| Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA | Q81547115 | ||
| Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery | Q83126421 | ||
| Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates | Q24646644 | ||
| Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes | Q28363716 | ||
| A combinatorial library of lipid-like materials for delivery of RNAi therapeutics | Q33330928 | ||
| Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses | Q33392252 | ||
| Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs | Q34436572 | ||
| Recent approaches to intracellular delivery of drugs and DNA and organelle targeting | Q36533366 | ||
| Delivery vehicles for small interfering RNA in vivo | Q37079140 | ||
| Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice | Q37111373 | ||
| Mechanism of oligonucleotide release from cationic liposomes | Q37255679 | ||
| Knocking down barriers: advances in siRNA delivery | Q37380671 | ||
| The polymorphic phase behaviour of phosphatidylethanolamines of natural and synthetic origin. A 31P NMR study | Q39221250 | ||
| Dependence of the bilayer to hexagonal phase transition on amphiphile chain length | Q39521527 | ||
| Lipid polymorphism and the roles of lipids in membranes | Q39793511 | ||
| Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids | Q40391286 | ||
| A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. | Q41627367 | ||
| Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures | Q41630941 | ||
| On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids | Q43710407 | ||
| RNAi-mediated gene silencing in non-human primates. | Q53630565 | ||
| Modulation of membrane fusion by asymmetric transbilayer distributions of amino lipids | Q57189862 | ||
| P433 | issue | 2 | |
| P921 | main subject | lipid | Q11367 |
| RNA design | Q55213896 | ||
| P304 | page(s) | 172-176 | |
| P577 | publication date | 2010-01-17 | |
| P1433 | published in | Nature Biotechnology | Q1893837 |
| P1476 | title | Rational design of cationic lipids for siRNA delivery | |
| P478 | volume | 28 |
| Q38074463 | 'Smart' non-viral delivery systems for targeted delivery of RNAi to the lungs |
| Q37258262 | A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo |
| Q52589409 | A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates. |
| Q64092752 | A T7 autogene-based hybrid mRNA/DNA system for long-term shRNA expression in cytoplasm without inefficient nuclear entry |
| Q34854015 | A bifurcated proteoglycan binding small molecule carrier for siRNA delivery. |
| Q35298225 | A method for concentrating lipid peptide DNA and siRNA nanocomplexes that retains their structure and transfection efficiency |
| Q47564392 | A modular platform for targeted RNAi therapeutics. |
| Q90687449 | A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model |
| Q49378127 | A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system. |
| Q41839754 | A simple protocol for preparation of a liposomal vesicle with encapsulated plasmid DNA that mediate high accumulation and reporter gene activity in tumor tissue |
| Q34013891 | A status report on RNAi therapeutics |
| Q42816512 | A unique and potent protein binding nature of liposome containing polyethylenimine and polyethylene glycol: a nondisplaceable property. |
| Q39100867 | Acid-degradable polymer-caged lipoplex (PCL) platform for siRNA delivery: facile cellular triggered release of siRNA |
| Q37976576 | Action and reaction: the biological response to siRNA and its delivery vehicles |
| Q88599910 | Advances in Biomaterials for Drug Delivery |
| Q41786279 | Advances in Lipid Nanoparticles for siRNA Delivery |
| Q40735074 | Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles. |
| Q98386176 | Advances in oligonucleotide drug delivery |
| Q57163340 | Ag@4ATP-coated liposomes: SERS traceable delivery vehicles for living cells |
| Q92448095 | Amphiphilic Polypeptides for VEGF siRNA Delivery into Retinal Epithelial Cells |
| Q57179653 | Amphiphilic dynamic NDI and PDI probes: imaging microdomains in giant unilamellar vesicles |
| Q36849024 | An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia |
| Q33877242 | An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA. |
| Q36333188 | An orthotopic bladder tumor model and the evaluation of intravesical saRNA treatment |
| Q90279299 | Analyzing 2000 in Vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery |
| Q39595680 | Apolipoprotein B knockdown by AAV-delivered shRNA lowers plasma cholesterol in mice |
| Q33901933 | Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. |
| Q42318134 | Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics |
| Q35857347 | Biocompatible and colloidally stabilized mPEG-PE/calcium phosphate hybrid nanoparticles loaded with siRNAs targeting tumors |
| Q39135315 | Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics |
| Q37679156 | Bioengineered nanoparticles for siRNA delivery |
| Q37594565 | Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery. |
| Q38971775 | Biomaterials in siRNA Delivery: A Comprehensive Review |
| Q38823188 | Biophysical experiments and simulation in nanoparticle-based drug delivery systems |
| Q38252307 | Biophysical properties of sphingosine, ceramides and other simple sphingolipids |
| Q37731666 | Bioreducible cationic polymer-based nanoparticles for efficient and environmentally triggered cytoplasmic siRNA delivery to primary human brain cancer cells |
| Q91730523 | Biorefinery via Achmatowicz Rearrangement: Synthesis of Pentane-1,2,5-triol from Furfuryl Alcohol |
| Q92493347 | Bis-Thioether-Containing Lipid Chains in Cationic Amphiphiles: Physicochemical Properties and Applications in Gene Delivery |
| Q47759890 | Boosting Intracellular Delivery of Lipid Nanoparticle-Encapsulated mRNA. |
| Q64261924 | Bottlebrush-architectured poly(ethylene glycol) as an efficient vector for RNA interference in vivo |
| Q38853141 | CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes |
| Q35785890 | Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor |
| Q28083065 | Cancer nanomedicine: from targeted delivery to combination therapy |
| Q38431604 | Cancer nanotherapeutics in clinical trials. |
| Q93057279 | Carriers Break Barriers in Drug Delivery: Endocytosis and Endosomal Escape of Gene Delivery Vectors |
| Q36463847 | Catalytic self-assembly of a DNA dendritic complex for efficient gene silencing |
| Q39366778 | Cationic Nanohydrogel Particles for Therapeutic Oligonucleotide Delivery |
| Q64249627 | Cationic Niosomes as Non-Viral Vehicles for Nucleic Acids: Challenges and Opportunities in Gene Delivery |
| Q33745473 | Cationic lipid nanodisks as an siRNA delivery vehicle |
| Q37275063 | Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor |
| Q39490162 | Cationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehicles |
| Q64911535 | Cationic micelle-based siRNA delivery for efficient colon cancer gene therapy. |
| Q37798545 | Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics |
| Q38788622 | Cationic switchable lipids: pH-triggered molecular switch for siRNA delivery. |
| Q41813002 | Cationic α-cyclodextrin:poly(ethylene glycol) polyrotaxanes for siRNA delivery |
| Q38733888 | Cellular environment-responsive nanomaterials for use in gene and siRNA delivery: molecular design for biomembrane destabilization and intracellular collapse |
| Q38162098 | Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology |
| Q38868870 | Chemically defined polyethylene glycol siRNA conjugates with enhanced gene silencing effect |
| Q38121824 | Chemistry and formulations for siRNA therapeutics |
| Q64244663 | Chemotherapy priming of the Pancreatic Tumor Microenvironment Promotes Delivery and Anti-Metastasis Efficacy of Intravenous Low-Molecular-Weight Heparin-Coated Lipid-siRNA Complex |
| Q39673421 | Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. |
| Q39813003 | Circular RNA interference effector molecules (WO10084371). |
| Q39417286 | Co-localization of fluorescent labeled lipid nanoparticles with specifically tagged subcellular compartments by single particle tracking at low nanoparticle to cell ratios |
| Q35853451 | Combinatorial Approach to Nanoarchitectonics for Nonviral Delivery of Nucleic Acids |
| Q36788349 | Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes |
| Q92907354 | Comparison between Lipofectamine RNAiMAX and GenMute transfection agents in two cellular models of human hepatoma |
| Q35775811 | Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo |
| Q38834667 | Concise postsynthetic preparation of oligonucleotide-oligopeptide conjugates through facile disulfide bond formation. |
| Q92980251 | Constrained Nanoparticles Deliver siRNA and sgRNA to T Cells In Vivo without Targeting Ligands |
| Q43997326 | Controlled nucleation of lipid nanoparticles |
| Q36130078 | Coordinated effects of microRNA-494 induce G₂/M arrest in human cholangiocarcinoma |
| Q88991452 | Corneal chemical burn treatment through a delivery system consisting of TGF-β1 siRNA: in vitro and in vivo |
| Q39230061 | Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes |
| Q28235733 | Current prospects for RNA interference-based therapies |
| Q92629953 | Current trends in targeted therapy for drug-resistant infections |
| Q57180333 | Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs |
| Q36204816 | Cystamine-terminated poly(beta-amino ester)s for siRNA delivery to human mesenchymal stem cells and enhancement of osteogenic differentiation |
| Q28383550 | Cytokines as biomarkers of nanoparticle immunotoxicity |
| Q37031903 | DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing |
| Q37636194 | Degradable Dextran Nanopolymer as a Carrier for Choline Kinase (ChoK) siRNA Cancer Therapy |
| Q33954008 | Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. |
| Q38180108 | Delivering colloidal nanoparticles to mammalian cells: a nano-bio interface perspective |
| Q63246454 | Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery |
| Q38226666 | Delivering the promise of small ncRNA therapeutics |
| Q38154803 | Delivery materials for siRNA therapeutics |
| Q38160246 | Delivery of RNAi therapeutics: work in progress |
| Q27008706 | Delivery of gene silencing agents for breast cancer therapy |
| Q61444662 | Delivery of mRNA to platelets using lipid nanoparticles |
| Q90391422 | Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation |
| Q27024646 | Delivery of oligonucleotides with lipid nanoparticles |
| Q35665154 | Delivery of siRNA to the mouse lung via a functionalized lipopolyamine |
| Q38471902 | Delivery of siRNAs to Dendritic Cells Using DEC205-Targeted Lipid Nanoparticles to Inhibit Immune Responses |
| Q38692510 | Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC. |
| Q38851942 | Delivery strategies: RNA interference in agriculture and human health |
| Q88502211 | Dendritic peptide bolaamphiphiles for siRNA delivery to primary adipocytes |
| Q34782034 | Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery |
| Q37031856 | Design of a platform technology for systemic delivery of siRNA to tumours using rolling circle transcription |
| Q37111734 | Design of siRNA Therapeutics from the Molecular Scale |
| Q89910193 | Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA |
| Q40295236 | Designer lipids advance systemic siRNA delivery |
| Q35816825 | Development and optimization of nanosomal formulations for siRNA delivery to the liver |
| Q51748839 | Development of Controlled Drug Delivery Systems for Bone Fracture-Targeted Therapeutic Delivery: A Review. |
| Q36299367 | Development of a 2',4'-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo |
| Q42272223 | Development of a low toxicity, effective pDNA vector based on noncovalent assembly of bioresponsive amino-β-cyclodextrin:adamantane-poly(vinyl alcohol)-poly(ethylene glycol) transfection complexes |
| Q38918257 | Development of lipoprotein(a) siRNAs for mechanism of action studies in non-human primate models of atherosclerosis |
| Q33768132 | Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system |
| Q27339704 | Direct cytosolic delivery of siRNA using nanoparticle-stabilized nanocapsules |
| Q39100525 | Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability |
| Q38289241 | Double-stranded RNA-binding artificial cationic oligosaccharides stabilizing siRNAs with a low N/P ratio |
| Q52783219 | Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition. |
| Q35150259 | Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes |
| Q49850199 | Effect of Chemical Modifications on Aptamer Stability in Serum. |
| Q50503418 | Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes. |
| Q36421379 | Effect of surface properties on liposomal siRNA delivery |
| Q42229992 | Effective nanoparticle-based gene delivery by a protease triggered charge switch |
| Q48418109 | Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model. |
| Q90240728 | Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo |
| Q38793629 | Efficient Transfection of siRNA by Peptide Dendrimer-Lipid Conjugates. |
| Q97636629 | Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle |
| Q47155492 | Efficient in vitro delivery of Noggin siRNA enhances osteoblastogenesis |
| Q39190427 | Emerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy |
| Q39315669 | Emerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy |
| Q26996159 | Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems |
| Q92706998 | Endocytic Profiling of Cancer Cell Models Reveals Critical Factors Influencing LNP-Mediated mRNA Delivery and Protein Expression |
| Q37990464 | Endocytosis at the nanoscale |
| Q47105498 | Engineered Zn(II)-Dipicolylamine-Gold Nanorod Provides Effective Prostate Cancer Treatment by Combining siRNA Delivery and Photothermal Therapy |
| Q90706949 | Engineered nanoparticles for systemic siRNA delivery to malignant brain tumours |
| Q39306702 | Engineering liposomal nanoparticles for targeted gene therapy |
| Q104073756 | Engineering precision nanoparticles for drug delivery |
| Q39080011 | Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations |
| Q36740249 | Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes |
| Q64964018 | Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. |
| Q38236693 | Enhancing siRNA delivery by employing lipid nanoparticles |
| Q38591825 | Enhancing the pharmacokinetic/pharmacodynamic properties of therapeutic nucleotides using lipid nanoparticle systems |
| Q37799614 | Enzyme-triggered nanomedicine: drug release strategies in cancer therapy. |
| Q41145076 | Evaluation of antitumor activity of survivin short interfering RNA delivered by lipid nanoparticles in colon cancer in vitro and in vivo |
| Q37258701 | Exploiting endocytosis for nanomedicines |
| Q39337138 | Fabrication of Low-Generation Dendrimers into Nanostructures for Efficient and Nontoxic Gene Delivery |
| Q37476252 | Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles |
| Q36114022 | Focused Library Approach to Discover Discrete Dipeptide Bolaamphiphiles for siRNA Delivery |
| Q34323964 | Formulation of Small Activating RNA Into Lipidoid Nanoparticles Inhibits Xenograft Prostate Tumor Growth by Inducing p21 Expression. |
| Q36130906 | Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells |
| Q34381259 | Gene Silencing of Human Neuronal Cells for Drug Addiction Therapy using Anisotropic Nanocrystals |
| Q34793765 | Glial cells in familial amyloidotic polyneuropathy |
| Q33724219 | Gold nanoparticles for nucleic acid delivery. |
| Q37727724 | Harnessing Nanoparticles for Immunomodulation and Vaccines |
| Q35673875 | Harnessing RNAi nanomedicine for precision therapy |
| Q38200096 | Hepatic RNA Interference: Delivery by Synthetic Vectors |
| Q57061947 | High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing |
| Q37338686 | Highly efficient cationic ethylphosphatidylcholine siRNA carrier for GFP suppression in modified breast cancer cells. |
| Q40689442 | How to Tackle the Challenge of siRNA Delivery with Sequence-Defined Oligoamino Amides |
| Q36485210 | Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model. |
| Q36708805 | Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer |
| Q37641455 | Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy |
| Q54216684 | Identification and application of exogenous dsRNA confers plant protection against Sclerotinia sclerotiorum and Botrytis cinerea. |
| Q35721260 | Identification of siRNA delivery enhancers by a chemical library screen |
| Q44591306 | Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape |
| Q38710046 | Imaging-guided delivery of RNAi for anticancer treatment |
| Q92576290 | Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology |
| Q38862110 | Improved Synthesis and In Vitro Evaluation of an Aptamer Ribosomal Toxin Conjugate |
| Q45767689 | Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation |
| Q42848073 | In Vivo Delivery of RNAi by Reducible Interfering Nanoparticles (iNOPs). |
| Q34393539 | In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight |
| Q38004708 | In vivo gene delivery by nonviral vectors: overcoming hurdles? |
| Q42426586 | In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR). |
| Q64094904 | In vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers |
| Q37718105 | In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus. |
| Q38213112 | Indian Hedgehog, a critical modulator in osteoarthritis, could be a potential therapeutic target for attenuating cartilage degeneration disease |
| Q37489356 | Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles |
| Q39913293 | Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. |
| Q38085679 | Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides. |
| Q35029188 | Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs. |
| Q37714008 | Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy. |
| Q38802167 | Innovative Technologies in Nanomedicines: From Passive Targeting to Active Targeting/From Controlled Pharmacokinetics to Controlled Intracellular Pharmacokinetics. |
| Q39003380 | Insight into mechanisms of cellular uptake of lipid nanoparticles and intracellular release of small RNAs. |
| Q38074461 | Inspired by nature: fundamentals in nanotechnology design to overcome biological barriers. |
| Q24306825 | Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter |
| Q36155481 | Intercalation-mediated nucleic acid nanoparticles for siRNA delivery |
| Q39351982 | Interfering nanoparticles for silencing microRNAs |
| Q36392469 | Internalization of Vectorized Liposomes Loaded with Plasmid DNA in C6 Glioma Cells. |
| Q48276890 | Intranasal delivery of antiviral siRNA. |
| Q37420589 | Investigation of siRNA Nanoparticle Formation Using Mono-Cationic Detergents and Its Use in Gene Silencing in Human HeLa Cells |
| Q28082939 | Knocking down disease: a progress report on siRNA therapeutics |
| Q36901850 | Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma |
| Q27349554 | Layered Double Hydroxide Nanotransporter for Molecule Delivery to Intact Plant Cells |
| Q57428850 | Leveraging Physiology for Precision Drug Delivery |
| Q92494345 | Ligand Conjugated Multimeric siRNAs Enable Enhanced Uptake and Multiplexed Gene Silencing |
| Q41822449 | Light-Triggerable Liposomes for Enhanced Endolysosomal Escape and Gene Silencing in PC12 Cells |
| Q64121037 | Light-Triggered Cellular Delivery of Oligonucleotides |
| Q34419873 | Light-scattering detection below the level of single fluorescent molecules for high-resolution characterization of functional nanoparticles |
| Q90261644 | Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells |
| Q92177878 | Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications |
| Q41810449 | Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain |
| Q39244558 | Lipid Nanoparticle Systems for Enabling Gene Therapies |
| Q89129500 | Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis |
| Q36211791 | Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core |
| Q39196485 | Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer |
| Q42377847 | Lipid nanoparticle delivery of glucagon receptor siRNA improves glucose homeostasis in mouse models of diabetes |
| Q39027758 | Lipid nanoparticle delivery systems for siRNA-based therapeutics |
| Q34233801 | Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo |
| Q97073785 | Lipid nanoparticle technology for therapeutic gene regulation in the liver |
| Q38269555 | Lipid nanoparticles for gene delivery |
| Q39339170 | Lipid nanoparticles for hepatic delivery of small interfering RNA. |
| Q38269558 | Lipid nanoparticles for short interfering RNA delivery |
| Q26741449 | Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside |
| Q38300777 | Lipid-based mRNA vaccine delivery systems |
| Q38172634 | Lipid-based nanoparticles in the systemic delivery of siRNA. |
| Q28828356 | Lipid-based vectors for siRNA delivery |
| Q34197336 | Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery |
| Q94562267 | Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver disease |
| Q91787712 | Lipid-mRNA Nanoparticle Designed to Enhance Intracellular Delivery Mediated by Shock Waves |
| Q37503581 | Lipid-modified aminoglycoside derivatives for in vivo siRNA delivery. |
| Q92462854 | Lipidoid-siRNA Nanoparticle-Mediated IL-1β Gene Silencing for Systemic Arthritis Therapy in a Mouse Model |
| Q37659987 | Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. |
| Q38300347 | Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01. |
| Q83460693 | Localized, targeted, and sustained siRNA delivery |
| Q28486060 | MICU2, a paralog of MICU1, resides within the mitochondrial uniporter complex to regulate calcium handling |
| Q45913428 | MMP-14 overexpression correlates with the neurodegenerative process in familial amyloidotic polyneuropathy. |
| Q38669909 | Mathematical Modeling: A Tool for Optimization of Lipid Nanoparticle-Mediated Delivery of siRNA. |
| Q36315291 | Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo |
| Q84969771 | Medicinal Chemistry of siRNA Delivery |
| Q41142901 | Membrane permeabilization induced by sphingosine: effect of negatively charged lipids |
| Q52585184 | Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine Applications. |
| Q39203809 | MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines |
| Q36602813 | MicroRNA Regulation of Atherosclerosis |
| Q37869804 | MicroRNA therapeutics. |
| Q28240056 | MicroRNAs 103 and 107 regulate insulin sensitivity |
| Q38205266 | MicroRNAs and drug resistance in prostate cancers |
| Q28087258 | MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics |
| Q36739805 | MicroRNAs in Liver Health and Disease |
| Q38683783 | MicroRNAs in dysfunctional adipose tissue: cardiovascular implications |
| Q38115932 | MicroRNAs in kidney diseases: new promising biomarkers for diagnosis and monitoring |
| Q42818425 | Microfluidic Assembly of Cationic-β-Cyclodextrin:Hyaluronic Acid-Adamantane Host:Guest pDNA Nanoparticles |
| Q36234343 | Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. |
| Q37217266 | Microfluidic assembly of lipid-based oligonucleotide nanoparticles |
| Q38288077 | Microfluidic self-assembly of folate-targeted monomolecular siRNA-lipid nanoparticles. |
| Q38918919 | Microfluidics: a transformational tool for nanomedicine development and production |
| Q33637385 | Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice |
| Q35884898 | Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model |
| Q27027657 | Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches |
| Q40077184 | Molecular Mechanisms and Biological Functions of siRNA. |
| Q39038777 | Monocyte targeting and activation by cationic liposomes formulated with a TLR7 agonist. |
| Q35688089 | Multifunctional cationic lipid-based nanoparticles facilitate endosomal escape and reduction-triggered cytosolic siRNA release |
| Q37088608 | Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery |
| Q36307467 | Nano-enabled delivery of diverse payloads across complex biological barriers |
| Q92876174 | Nanocarrier Lipid Composition Modulates the Impact of Pulmonary Surfactant Protein B (SP-B) on Cellular Delivery of siRNA |
| Q38555082 | Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents |
| Q27692125 | Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides |
| Q33633338 | Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity |
| Q47251513 | Nanoparticle delivery of RNA-based therapeutics to alter the vocal fold tissue response to injury. |
| Q38037048 | Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy |
| Q39007153 | Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model. |
| Q58691112 | Nanoparticles Escaping RES and Endosome: Challenges for siRNA Delivery for Cancer Therapy |
| Q58610675 | Nanoparticles that deliver RNA to bone marrow identified by in vivo directed evolution |
| Q39091854 | Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems |
| Q91595721 | Nanotechnology for organ-tunable gene editing |
| Q34112647 | Nanotechnology in drug delivery and tissue engineering: from discovery to applications |
| Q35086721 | Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. |
| Q36763827 | Neutral polymeric micelles for RNA delivery |
| Q39673568 | New Amphiphilic Carriers Forming pH-Sensitive Nanoparticles for Nucleic Acid Delivery |
| Q37277425 | New aspects of gene-silencing for the treatment of cardiovascular diseases |
| Q34003800 | Next generation delivery system for proteins and genes of therapeutic purpose: why and how? |
| Q42181014 | Niosomes based on synthetic cationic lipids for gene delivery: the influence of polar head-groups on the transfection efficiency in HEK-293, ARPE-19 and MSC-D1 cells. |
| Q38782167 | Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA. |
| Q92561933 | Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets |
| Q35208236 | Non-viral nanoparticle delivers small interfering RNA to macrophages in vitro and in vivo |
| Q38849963 | Non-viral nucleic acid containing nanoparticles as cancer therapeutics |
| Q34429032 | Non-viral vectors for gene-based therapy |
| Q38571809 | Nonionic surfactant vesicles for delivery of RNAi therapeutics |
| Q36221799 | Nonviral delivery of self-amplifying RNA vaccines |
| Q39307397 | Novel lipoidal amine-based nanocarrier formulations for siRNA delivery. |
| Q26851886 | Nucleic acid delivery: the missing pieces of the puzzle? |
| Q38199151 | Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines |
| Q40405926 | Nucleoside Modified mRNA Vaccines for Infectious Diseases |
| Q38123854 | Oligonucleotide conjugates for therapeutic applications. |
| Q37803214 | Oligonucleotide delivery in cancer therapy |
| Q35163373 | Oligonucleotide delivery: a patent review (2010 - 2013). |
| Q38618638 | Oligonucleotide therapeutics: chemistry, delivery and clinical progress |
| Q63246495 | Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines |
| Q48116928 | Optimized Solid-Phase-Assisted Synthesis of Oleic Acid Containing siRNA Nanocarriers |
| Q30235525 | Overcoming cellular barriers for RNA therapeutics |
| Q39339350 | Overcoming nonviral gene delivery barriers: perspective and future |
| Q50497881 | Pendant polymer:amino-β-cyclodextrin:siRNA guest:host nanoparticles as efficient vectors for gene silencing. |
| Q30455490 | Perspectives and opportunities for nanomedicine in the management of atherosclerosis. |
| Q38707859 | Photocrosslinkable, biodegradable hydrogels with controlled cell adhesivity for prolonged siRNA delivery to hMSCs to enhance their osteogenic differentiation |
| Q47607348 | Pieter Cullis' quest for a lipid-based, fusogenic delivery system for nucleic acid therapeutics: success with siRNA so what about mRNA? |
| Q42910801 | Pieter Cullis: an outstanding lipid biophysicist, drug delivery scientist, educator, and entrepreneur |
| Q37613212 | Poly(glycoamidoamine) Brushes Formulated Nanomaterials for Systemic siRNA and mRNA Delivery in Vivo |
| Q36980520 | PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery |
| Q46444001 | Polycation liposomes as a vector for potential intracellular delivery of microRNA. |
| Q30372383 | Polymeric Nanostructures for Imaging and Therapy |
| Q35127438 | Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo. |
| Q37780603 | Potential use of RNA interference in cancer therapy |
| Q42867066 | Preclinical development of siRNA therapeutics for AL amyloidosis. |
| Q36981555 | Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis |
| Q38725307 | Preliminary study of a novel transfection modality for in vivo siRNA delivery to vocal fold fibroblasts |
| Q34719114 | Preparation of novel curdlan nanoparticles for intracellular siRNA delivery |
| Q52590993 | Progress and challenges towards targeted delivery of cancer therapeutics. |
| Q33865784 | Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection. |
| Q28255877 | Progress toward in vivo use of siRNAs-II |
| Q48122525 | Promising effects of nanomedicine in cancer drug delivery |
| Q34482403 | Protection against West Nile virus infection in mice after inoculation with type I interferon-inducing RNA transcripts. |
| Q37520171 | Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA. |
| Q52605511 | Protective effect of Gelofusine against cRGD-siRNA-induced nephrotoxicity in mice. |
| Q37847687 | Pulmonary delivery of therapeutic siRNA. |
| Q92162442 | RNA Therapeutics: How Far Have We Gone? |
| Q38019046 | RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics |
| Q47565462 | RNA interference-based therapy and its delivery systems |
| Q34248493 | RNA therapeutics: beyond RNA interference and antisense oligonucleotides |
| Q41522655 | RNAi in murine hepatocytes: the agony of choice--a study of the influence of lipid-based transfection reagents on hepatocyte metabolism |
| Q37445494 | RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction. |
| Q92545193 | RNAi therapeutic strategies for acute respiratory distress syndrome |
| Q37866632 | RNAi-based therapeutic strategies for metabolic disease |
| Q92747927 | ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer |
| Q47151105 | Rapid, Single-Cell Analysis and Discovery of Vectored mRNA Transfection In Vivo with a loxP-Flanked tdTomato Reporter Mouse |
| Q38321588 | Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia |
| Q63246374 | Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases |
| Q34165321 | Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors |
| Q38241667 | Recent advances in characterization of nonviral vectors for delivery of nucleic acids: impact on their biological performance |
| Q47666014 | Recent advances of controlled drug delivery using microfluidic platforms. |
| Q37851364 | Recent synthetic transport systems |
| Q39225594 | Recombinant high density lipoprotein nanoparticles for target-specific delivery of siRNA. |
| Q35975665 | Reductively responsive siRNA-conjugated hydrogel nanoparticles for gene silencing |
| Q34466211 | Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma |
| Q90362515 | Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery |
| Q28396399 | Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA |
| Q45875385 | Rod-Shaped Active Drug Particles Enable Efficient and Safe Gene Delivery. |
| Q46031803 | Role of In Vitro Release Methods in Liposomal Formulation Development: Challenges and Regulatory Perspective. |
| Q61443535 | Ruthenium-containing supramolecular nanoparticles based on bipyridine-modified cyclodextrin and adamantyl PEI with DNA condensation properties |
| Q39431804 | SPANosomes as delivery vehicles for small interfering RNA (siRNA). |
| Q46250879 | Safety Evaluation of Lipid Nanoparticle-Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey |
| Q58794823 | Scaffolds as Structural Tools for Bone-Targeted Drug Delivery |
| Q36269077 | Scalable preparation of poly(ethylene glycol)-grafted siRNA-loaded lipid nanoparticles using a commercially available fluidic device and tangential flow filtration |
| Q28834046 | Screening of efficient siRNA carriers in a library of surface-engineered dendrimers |
| Q38776971 | Selective nuclear localization of siRNA by metallic versus semiconducting single wall carbon nanotubes in keratinocytes. |
| Q64969500 | Self-Crosslinking Lipopeptide/DNA/PEGylated Particles: A New Platform for DNA Vaccination Designed for Assembly in Aqueous Solution. |
| Q47212600 | Self-Transfecting Micellar RNA: Modulating Nanoparticle Cell Interactions via High Density Display of Small Molecule Ligands on Micelle Coronas |
| Q37662457 | Self-assembled RNA interference microsponges for efficient siRNA delivery |
| Q50233841 | Self-organization of Nucleic Acids in Lipid Constructs. |
| Q38265619 | Sequence-defined shuttles for targeted nucleic acid and protein delivery |
| Q29039090 | Silencing disease genes in the laboratory and the clinic |
| Q35737489 | Silencing of CCR2 in myocarditis |
| Q92093184 | Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles |
| Q85397374 | Single-stranded siRNAs for in vivo gene silencing |
| Q34120092 | Small RNA combination therapy for lung cancer |
| Q32174291 | Small interfering RNA targeting of the survivin gene inhibits human tumor cell growth in vitro |
| Q64070969 | Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach |
| Q34485522 | Strategies to deliver microRNAs as potential therapeutics in the treatment of cardiovascular pathology. |
| Q36091258 | Structure-Based Design of Dendritic Peptide Bolaamphiphiles for siRNA Delivery |
| Q52626761 | Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. |
| Q34485756 | Switchable Lipids: Conformational Change for Fast pH-Triggered Cytoplasmic Delivery |
| Q94948489 | Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver |
| Q35238275 | Synergistic silencing: combinations of lipid-like materials for efficacious siRNA delivery |
| Q47954152 | Synthesis and Biological Evaluation of Ionizable Lipid Materials for the In Vivo Delivery of Messenger RNA to B Lymphocytes. |
| Q34270142 | Synthesis of an enlarged library of dynamic DNA activators with oxime, disulfide and hydrazone bridges |
| Q36651464 | Synthesis, characterization, and evaluation of ionizable lysine-based lipids for siRNA delivery |
| Q36053809 | Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells. |
| Q51131993 | Targeted Co-delivery of PTX and TR3 siRNA by PTP Peptide Modified Dendrimer for the Treatment of Pancreatic Cancer. |
| Q37636279 | Targeted Sterically Stabilized Phospholipid siRNA Nanomedicine for Hepatic and Renal Fibrosis |
| Q34025149 | Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms |
| Q41777416 | Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies |
| Q34943809 | Targeting DNA vaccines to myeloid cells using a small peptide |
| Q37775105 | Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer. |
| Q38090525 | Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery |
| Q92735297 | Testing thousands of nanoparticles in vivo using DNA barcodes |
| Q44134724 | The AGMA1 polyamidoamine mediates the efficient delivery of siRNA. |
| Q42212141 | The Business of RNAi Therapeutics in 2012 |
| Q64957624 | The Mechanism for siRNA Transmembrane Assisted by PMAL. |
| Q36134911 | The Niemann-Pick C1 Inhibitor NP3.47 Enhances Gene Silencing Potency of Lipid Nanoparticles Containing siRNA. |
| Q91698476 | The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs |
| Q57149600 | The Structure-To-Function Relationships of Gammaherpesvirus-Encoded Long Non-Coding RNAs and Their Contributions to Viral Pathogenesis |
| Q38382964 | The application of RNAi-based treatments for inflammatory bowel disease |
| Q92209450 | The current state and future directions of RNAi-based therapeutics |
| Q37210936 | The delivery of therapeutic oligonucleotides |
| Q33846059 | The roles of individual mammalian argonautes in RNA interference in vivo |
| Q38555085 | Therapeutic and safety considerations of nanoparticle-mediated drug delivery in pregnancy |
| Q37330601 | Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system |
| Q33652566 | Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo |
| Q38296021 | Therapeutic oligonucleotides with polyethylene glycol modifications. |
| Q96609193 | Therapeutic siRNA: state of the art |
| Q36472802 | Toward personalized cancer nanomedicine - past, present, and future |
| Q51700936 | Transcytosis-Targeting Peptide: A Conductor of Liposomal Nanoparticles through the Endothelial Cell Barrier. |
| Q57139324 | Transfection by cationic gemini lipids and surfactants |
| Q35616785 | Transthyretin Induces Insulin-like Growth Factor I Nuclear Translocation Regulating Its Levels in the Hippocampus |
| Q36206440 | Treatment of erythropoietin deficiency in mice with systemically administered siRNA. |
| Q36076260 | Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery |
| Q34313026 | Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA. |
| Q36757152 | U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo |
| Q51044431 | Ultrasound-Mediated Delivery of RNA to Colonic Mucosa of Live Mice. |
| Q33859472 | Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy |
| Q92983106 | Using macropinocytosis for intracellular delivery of therapeutic nucleic acids to tumour cells |
| Q27694686 | Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline |
| Q30834506 | Visualization of self-delivering hydrophobically modified siRNA cellular internalization. |
| Q27313970 | Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown |
| Q88530633 | Watching the gorilla and questioning delivery dogma |
| Q64084787 | What Drives Innovation: The Canadian Touch on Liposomal Therapeutics |
| Q52711221 | Worth the RISC? |
| Q92178008 | Yeast-Derived β-Glucan in Cancer: Novel Uses of a Traditional Therapeutic |
| Q33711685 | mRNA vaccine delivery using lipid nanoparticles |
| Q38252360 | mRNA-based therapeutics--developing a new class of drugs |
| Q27023295 | miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents |
| Q37087260 | pH-responsive biodegradable assemblies containing tunable phenyl-substituted vinyl ethers for use as efficient gene delivery vehicles. |
| Q33708003 | pH-responsive polymeric micelle carriers for siRNA drugs |
| Q33611947 | siRNA Delivery Strategies: A Comprehensive Review of Recent Developments |
| Q34327430 | siRNA delivery for the treatment of ovarian cancer |
| Q38043064 | siRNA delivery: from lipids to cell-penetrating peptides and their mimics |
| Q35261103 | siRNA for Influenza Therapy |
| Q47849903 | siRNA-mediated knockdown of P450 oxidoreductase in rats: a tool to reduce metabolism by CYPs and increase exposure of high clearance compounds |
Search more.